HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
HOOKIPA Pharma (NASDAQ: HOOK) announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York. Key highlights include:
1. Management team will host one-on-one meetings with investors.
2. CEO Dr. Malte Peters will participate in a Fireside Chat on September 9, 2024, at 1:30 p.m. ET.
3. The Fireside Chat will be available via webcast with a replay accessible for 90 days.
4. HOOKIPA is developing a new class of immunotherapeutics based on its proprietary arenavirus platform.
This event provides an opportunity for investors to gain insights into HOOKIPA's innovative approach to immunotherapy and its potential impact on the biotechnology sector.
HOOKIPA Pharma (NASDAQ: HOOK) ha annunciato la sua partecipazione al 26° Annual Global Investment Conference di H.C. Wainwright dal 9 all'11 settembre 2024, a New York. I punti salienti includono:
1. Il team di gestione ospiterà incontri one-to-one con gli investitori.
2. Il CEO Dr. Malte Peters parteciperà a un Fireside Chat il 9 settembre 2024, alle 13:30 ET.
3. Il Fireside Chat sarà disponibile tramite webcast con una registrazione accessibile per 90 giorni.
4. HOOKIPA sta sviluppando una nuova classe di immunoterapici basata sulla sua piattaforma proprietaria di arenavirus.
Questo evento offre un'opportunità per gli investitori di ottenere informazioni sull'approccio innovativo di HOOKIPA all'immunoterapia e il suo potenziale impatto nel settore biotecnologico.
HOOKIPA Pharma (NASDAQ: HOOK) anunció su participación en la 26ª Conferencia Anual de Inversión Global de H.C. Wainwright del 9 al 11 de septiembre de 2024 en Nueva York. Los puntos destacados incluyen:
1. El equipo de gestión llevará a cabo reuniones uno a uno con los inversores.
2. El CEO Dr. Malte Peters participará en un Fireside Chat el 9 de septiembre de 2024 a la 1:30 p.m. ET.
3. El Fireside Chat estará disponible a través de webcast con una repetición accesible durante 90 días.
4. HOOKIPA está desarrollando una nueva clase de inmunoterapéuticos basada en su plataforma de arenavirus patentada.
Este evento ofrece una oportunidad para que los inversores obtengan información sobre el enfoque innovador de HOOKIPA hacia la inmunoterapia y su posible impacto en el sector biotecnológico.
HOOKIPA Pharma (NASDAQ: HOOK)이 2024년 9월 9일부터 11일까지 뉴욕에서 열리는 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 주요 하이라이트는 다음과 같습니다:
1. 경영팀이 투자자와 개별 회의를 주최할 것입니다.
2. CEO Dr. Malte Peters가 2024년 9월 9일 오후 1시 30분 ET에 파이어사이드 챗에 참석합니다.
3. 파이어사이드 챗은 웹캐스트를 통해 제공되며 90일 동안 재생 가능합니다.
4. HOOKIPA는 독점적인 아레나바이러스 플랫폼을 기반으로 한 신규 면역치료제 클래스를 개발하고 있습니다.
이 행사는 투자자에게 HOOKIPA의 혁신적인 면역치료 접근 방식과 생명공학 분야에 미칠 잠재적 영향에 대한 통찰력을 얻을 수 있는 기회를 제공합니다.
HOOKIPA Pharma (NASDAQ: HOOK) a annoncé sa participation à la 26ème Conférence Annuelle des Investissements Globaux de H.C. Wainwright qui se déroulera du 9 au 11 septembre 2024 à New York. Les points clés comprennent :
1. L'équipe de direction organisera des réunions individuelles avec les investisseurs.
2. Le CEO Dr. Malte Peters participera à un Fireside Chat le 9 septembre 2024 à 13h30 ET.
3. Le Fireside Chat sera disponible en webcast avec un replay accessible pendant 90 jours.
4. HOOKIPA développe une nouvelle classe d'immunothérapeutiques basée sur sa plateforme propriétaire d'arénavirus.
Cet événement offre aux investisseurs l'opportunité d'acquérir des informations sur l'approche innovante de HOOKIPA en matière d'immunothérapie et son impact potentiel sur le secteur biotechnologique.
HOOKIPA Pharma (NASDAQ: HOOK) hat seine Teilnahme an der 26. jährlichen Global Investment Conference von H.C. Wainwright vom 9. bis 11. September 2024 in New York bekannt gegeben. Die wichtigsten Highlights sind:
1. Das Managementteam wird Einzelgespräche mit Investoren führen.
2. CEO Dr. Malte Peters wird am 9. September 2024 um 13:30 Uhr ET an einem Fireside Chat teilnehmen.
3. Der Fireside Chat wird über einen Webcast verfügbar sein, mit einer Aufzeichnung, die 90 Tage lang zugänglich ist.
4. HOOKIPA entwickelt eine neue Klasse von Immuntherapeutika basierend auf ihrer proprietären Arenaviren-Plattform.
Diese Veranstaltung bietet Investoren die Möglichkeit, Einblicke in den innovativen Ansatz von HOOKIPA zur Immuntherapie und deren potenzielle Auswirkungen auf den Biotechnologiesektor zu gewinnen.
- None.
- None.
NEW YORK and VIENNA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”, the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that members of the management team will participate in the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9th-11th, 2024 in New York.
Dr. Malte Peters, Hookipa’s Chief Executive Officer, and Terry Coelho, Executive Vice President & Chief Financial Officer will be hosting one-on-one meetings with investors during the conference. In addition, Dr. Peters will participate in a Fireside Chat on Monday, September 9, 2024 at 1:30 p.m. ET.
The fireside chat will be available via webcast through the following link: https://journey.ct.events/view/a5640121-61ef-4c2b-8017-b6b346ca2547
A replay of this webcast will be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events. Archived replays will be accessible for 90 days following each event.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.
Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
chuck@lifesciadvisors.com
FAQ
When is HOOKIPA Pharma (HOOK) participating in the H.C. Wainwright Global Investment Conference?
Who from HOOKIPA Pharma (HOOK) will be presenting at the conference?
How can investors access HOOKIPA Pharma's (HOOK) Fireside Chat at the conference?
What type of technology is HOOKIPA Pharma (HOOK) developing?
